A Study of INS365 Ophthalmic Solution in Patients With Moderate to Severe Dry Eye Disease
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of Multiple Ocular Instillations of INS365 Ophthalmic Solution vs. Placebo in Patients With Moderate to Severe Dry Eye Disease
Study Start Date :
Actual Primary Completion Date :
Actual Study Completion Date :
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
Child, Adult, Senior
Best corrected visual acuity of at least +0.7 ETDRS
Six month history of dry eye disease
Mild severity in two out of five symptoms
Unanesthetized Schirmer score of less than or equal to 7mm
Corneal fluorescein staining greater than or equal to 4 out of 15 or lissamine green conjunctival staining of greater than or equal to 5 out of 18
Nasal stimulated Schirmer score of less than 3mm
Have ongoing ocular infection
Have congenitally absent meibomian or lacrimal glands
Have had punctal occlusion within a specified time prior to study